• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Bausch + Lomb Launches Xipere for Macular Edema


Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

Bausch + Lomb has launched Xipere (triamcinolone acetonide injectable suspension), the first therapy approved the treatment of macular edema associated with uveitis, a form of eye inflammation.

Macular edema is the buildup of fluid in the macula, which causes retinal swelling and distorted vision, and if left untreated, may lead to permanent vision loss. It is delivered using the SCS Microinjector developed by Clearside Biomedical.

Steven Yeh, M.D.

Steven Yeh, M.D.

“Suprachoroidal administration, which provides exceptional access and high bioavailability to the posterior segment of the eye, has been well tolerated by patients, Steven Yeh, M.D., professor of Ophthalmology and director of Retinal Disease and Uveitis, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, and principal investigator for the Xipere phase 3 pivotal study, said in a press release.

“This administration technique is unlike traditional intraocular administration, and therefore, training for how to properly inject patients with this new medicine is important. I encourage eye care professionals to take advantage of the trainings being offered by Bausch + Lomb," he said.

The FDA approved Xipere in October 2021.

Related: FDA Approves Targeted Therapy for Macular Edema

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.